Why Medtronic Stock Got Off to a Roaring Start This Week
It isn't unusual for top medical device maker (NYSE: MDT) to score regulatory approvals for its goods. Nevertheless, in the healthcare field, nearly any regulatory win is considered a convincing victory for the company behind the product.
That was the dynamic behind the more than 2% bump in share price Medtronic enjoyed on Monday. That performance topped the broader stock market, at least if we go by the 1.4% rise of the benchmark S 500 index.
Early Monday afternoon, Medtronic reported that its Percept RC Deep Brain Stimulation (DBS) system had received approval from the U.S. Food and Drug Administration (FDA).
Source Fool.com
Medtronic plc Aktie
81,10 €
0,78 %
Eine Tendenz zu Buy-Einschätzungen bei Medtronic plc, überwiegend gegenüber Sell-Einschätzungen.
Ein Kursziel von 94 € für Medtronic plc zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 81.1 €.
